Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 3/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 5/20 | 0.44 |
| ▸ | RAF1 | P04049 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.44 |
| ▸ | LCK | P06239 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063049 | 1.00 | NPSR1 (0.51) | NPSR1MAPTKDM4EKITDDR1 | |
| SCHEMBL25791177 | 0.93 | KDM4E (0.42) | NPSR1MAPTKDM4EKITDDR1 | |
| SCHEMBL21054469 | 0.90 | NPSR1 (0.43) | NPSR1MAPTKDM4EKITDDR1 | |
| SCHEMBL30062654 | 0.90 | NPSR1 (0.43) | NPSR1MAPTKDM4EKITDDR1 | |
| SCHEMBL21090663 | 0.88 | MAPT (0.49) | MAPTKDM4EAURKARAF1BRAF | |
| SCHEMBL21053189 | 0.87 | AURKA (0.53) | MAPTKDM4EAURKAAKR1C3AKR1C2 | |
| SCHEMBL30061304 | 0.87 | AURKA (0.53) | MAPTKDM4EAURKAAKR1C3AKR1C2 | |
| SCHEMBL25791162 | 0.81 | ROCK2 (0.42) | AURKAMAPK14ROCK2CYP3A4CYP2D6 | |
| SCHEMBL25791202 | 0.81 | ROCK1 (0.44) | MAPTKDM4EKITDDR1AURKA | |
| SCHEMBL25791183 | 0.79 | AURKA (0.44) | MAPTKDM4EAURKAAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11524943-B1 | Benzocarbonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524943-B1 | Benzocarbonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| EP-3720430-A1 | BENZOCARBONYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2019113236-A1 | BENZOCARBONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113236-A1 | BENZOCARBONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524943-B1 | Benzocarbonyl compounds | YAP1, TEAD2, TEAD3 | NPSR1 4515/4885MAPT 1776/4885KDM4E 986/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | NPSR1 4607/4885MAPT 516/4885KDM4E 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.